CARLSBAD, Calif
Targazyme Inc., a late clinical-stage biopharmaceutical company developing novel fucosyltransferase enzyme technologies and products to improve clinical efficacy, safety, and cost of care outcomes for immuno-oncology and stem cell transplantation, announced that it has recruited cancer immunotherapy industry veteran James Caggiano to be the CEO, focused initially on its oncology business.
We welcome Jim Caggiano to our Targazyme team and look forward to his leadership with advancing our oncology assets to making a life-changing difference for cancer patients and their families worldwide, said Lynnet Koh, Targazyme's Founder and Executive Chairman of Targazyme. Caggiano brings a track record of delivering major shareholder value through successful execution of sell-side deal transactions and driving major commercial revenue growth. His military leadership skills positions the company for consistently delivering on key milestones on time and on budget.
I'm honored to join Targazyme at this exciting and pivotal time in its history, said Caggiano. I look forward to working with the team here to capitalize on the impressive results of the past and to move these very promising, life-saving therapies forward, ultimately enhancing the lives of cancer patients.
Disclaimer: This story was supplied by an external content provider; we do not endorse or accept responsibility for its accuracy, completeness, or any outcomes from relying on it. It is for informational purposes only and does not constitute legal, financial, medical, or other professional advice. Laws and regulations vary and may change; readers should verify accuracy and compliance with local requirements and consult a qualified professional for tailored guidance.